Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis
dc.contributor.author | Stidham, R. W. | en_US |
dc.contributor.author | Lee, T. C. H. | en_US |
dc.contributor.author | Higgins, P. D. R. | en_US |
dc.contributor.author | Deshpande, A. R. | en_US |
dc.contributor.author | Sussman, D. A. | en_US |
dc.contributor.author | Singal, A. G. | en_US |
dc.contributor.author | Elmunzer, B. J. | en_US |
dc.contributor.author | Saini, S. D. | en_US |
dc.contributor.author | Vijan, S. | en_US |
dc.contributor.author | Waljee, A. K. | en_US |
dc.date.accessioned | 2014-03-05T18:19:14Z | |
dc.date.available | 2015-06-01T15:48:45Z | en_US |
dc.date.issued | 2014-04 | en_US |
dc.identifier.citation | Stidham, R. W.; Lee, T. C. H.; Higgins, P. D. R.; Deshpande, A. R.; Sussman, D. A.; Singal, A. G.; Elmunzer, B. J.; Saini, S. D.; Vijan, S.; Waljee, A. K. (2014). "Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis." Alimentary Pharmacology & Therapeutics 39(7): 660-671. | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/106149 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | Agency for Healthcare Research and Quality (US) | en_US |
dc.title | Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/106149/1/apt12644.pdf | |
dc.identifier.doi | 10.1111/apt.12644 | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.identifier.citedreference | Du Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti‐tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560 – 8. | en_US |
dc.identifier.citedreference | Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003; 327: 557 – 60. | en_US |
dc.identifier.citedreference | GeMTC: network meta‐analysis software. Available at: http://drugis.org/gemtc. | en_US |
dc.identifier.citedreference | Thorlund K, Mills EJ. Sample size and power considerations in network meta‐analysis. Syst Rev 2012; 1: 41. | en_US |
dc.identifier.citedreference | Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308 – 16. | en_US |
dc.identifier.citedreference | Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor α agents. Inflamm Bowel Dis 2007; 13: 1323 – 32. | en_US |
dc.identifier.citedreference | Vos ACW, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti‐tumor necrosis factor‐ α antibodies induce regulatory macrophages in an Fc region‐dependent manner. Gastroenterology 2011; 140: 221 – 30. | en_US |
dc.identifier.citedreference | Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti‐tumor necrosis factor‐alpha agents. Clin Gastroenterol Hepatol 2013; 11: 826 – 31. | en_US |
dc.identifier.citedreference | Osterman MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and adalimumab for Crohn's Disease. Clin Gastroenterol Hepatol 2013; doi: 10.1016/j.cgh.2013.06.010 [Epub ahead of print]. | en_US |
dc.identifier.citedreference | Sussman DA, Kubiliun N, Mulani PM, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012; 18: 2043 – 55. | en_US |
dc.identifier.citedreference | Choi GKH, Collins SDE, Greer DP, et al. Costs of adalimumab versus infliximab as first‐line biological therapy for luminal Crohn's disease. J Crohns Colitis 2013; doi: 10.1016/j.crohns.2013.09.017 [Epub ahead of print]. | en_US |
dc.identifier.citedreference | Singh S, Nagpal SJ, Murad MH, et al. Inflammatory Bowel disease is associated with an increased risk of melanoma: a systematic review and meta‐analysis. Clinical Gastroenterol Hepatol 2014; 12: 210 – 8. | en_US |
dc.identifier.citedreference | Ford AC, Peyrin‐Biroulet L. Opportunistic infections with anti‐tumor necrosis factor‐alpha therapy in inflammatory bowel disease: meta‐analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 1268 – 76. | en_US |
dc.identifier.citedreference | Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti‐tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta‐analysis. Clinical Gastroenterol Hepatol 2009; 7: 874 – 81. | en_US |
dc.identifier.citedreference | Williams CJ, Peyrin‐Biroulet L, Ford AC. Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39: 447 – 458. | en_US |
dc.identifier.citedreference | Chilton F, Collett RA. Treatment choices, preferences and decision‐making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1 – 14. | en_US |
dc.identifier.citedreference | Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti‐TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49: 289 – 94. | en_US |
dc.identifier.citedreference | Renna S, Camma C, Modesto I, et al. Meta‐analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008; 135: 1500 – 9. | en_US |
dc.identifier.citedreference | Rangwalla SC, Waljee AK, Higgins PDR. Voting with their feet (VWF) endpoint: a meta‐analysis of an alternative endpoint in clinical trials, using 5‐ASA induction studies in ulcerative colitis. Inflamm Bowel Dis 2009; 15: 422 – 8. | en_US |
dc.identifier.citedreference | Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1 – 134. | en_US |
dc.identifier.citedreference | Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009; 338: b1147. | en_US |
dc.identifier.citedreference | Coleman CI, Phung O, Cappelleri JC, et al. Use of Mixed Treatment Comparisons in Systematic Reviews [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US), 2012. | en_US |
dc.identifier.citedreference | Thorlund K, Druyts E, Aviña‐Zubieta JA, Wu P, Mills EJ. Why the findings of published multiple treatment comparison meta‐analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 2013; 72: 1524 – 35. | en_US |
dc.identifier.citedreference | AHRQ. Methods Research Report ‐ Findings of Bayesian Mixed Treatment Comparison Meta‐Analyses: Comparison and Exploration Using Real‐World Trial Data and Simulation. 2013: 1–143. | en_US |
dc.identifier.citedreference | Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 1135 – 40. | en_US |
dc.identifier.citedreference | Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health‐related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101 – 9. | en_US |
dc.identifier.citedreference | Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010; 31: 693 – 707. | en_US |
dc.identifier.citedreference | Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471 – 8. | en_US |
dc.identifier.citedreference | Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780 – 7. | en_US |
dc.identifier.citedreference | Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology 2012; 142: 257 – 65.e1–3. | en_US |
dc.identifier.citedreference | Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology 2014; 146: 85 – 95. | en_US |
dc.identifier.citedreference | Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998 – 1002. | en_US |
dc.identifier.citedreference | Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462 – 76. | en_US |
dc.identifier.citedreference | Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology 2014; 146: 96 – 109. e1. | en_US |
dc.identifier.citedreference | Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61: 229 – 34. | en_US |
dc.identifier.citedreference | Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. | en_US |
dc.identifier.citedreference | Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5‐aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625 – 9. | en_US |
dc.identifier.citedreference | Schoenfeld P, Cook D, Hamilton F, Laine L, Morgan D, Peterson W. An evidence‐based approach to gastroenterology therapy. Evidence‐Based Gastroenterology Steering Group. Gastroenterology 1998; 114: 1318 – 25. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.